Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold. Analyst Price Forecast Suggests 63.45% Upside As of April 1, 2025, the ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Biogen Inc. (BIIB) shares rallied 5.7% in the last trading session to close at $120.49. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...